CTLGA9 Interacts with ALP1 and APN Receptors To Modulate Cry11Aa Toxicity in Aedes aegypti

Related Experiment Video

Updated: Jan 21, 2026

Maintaining Aedes aegypti Mosquitoes Infected with Wolbachia
09:23

Maintaining Aedes aegypti Mosquitoes Infected with Wolbachia

Published on: August 14, 2017

14.7K

Khadija Batool1, Intikhab Alam2, Liang Jin1

  • 1State Key Laboratory of Ecological Pest Control for Fujian and Taiwan Crops, College of Life Sciences, Key Lab of Biopesticides and Chemical Biology, MOE , Fujian Agriculture and Forestry University , 350002 Fuzhou , Fujian , PR China.

Journal of Agricultural and Food Chemistry
|July 25, 2019
PubMed

Insights

A newly identified C-type lectin, CTLGA9, in Aedes aegypti mosquitoes interferes with Bacillus thuringiensis Cry toxins. This interaction reduces mosquito larvicidal activity, offering new strategies for disease vector control.

Area of Science:

  • Entomology
  • Molecular Biology
  • Biochemistry

Background:

  • Aedes aegypti mosquitoes transmit numerous human viral diseases like Dengue, Zika, and Chikungunya.
  • Bacillus thuringiensis (Bt) produces Cry toxins, a biopesticide targeting mosquito larvae by binding to receptors like alkaline phosphatase (ALP) and aminopeptidase-N (APN).

Purpose of the Study:

  • To investigate the role of the C-type lectin CTLGA9 in Aedes aegypti in response to Bacillus thuringiensis Cry toxins.
  • To elucidate the molecular mechanisms underlying the interaction between CTLGA9 and Cry toxins.

Main Methods:

  • Far-western blot and ELISA were used to determine protein interactions.
  • Brush border membrane vesicles (BBMVs) from A. aegypti larvae were utilized.
  • Molecular docking simulations were performed to analyze binding site interactions.
  • Larvicidal toxicity assays were conducted to assess the impact on Cry toxin efficacy.

Main Results:

  • The CTLGA9 protein was found to interact with A. aegypti larval BBMVs, specifically with ALP1, APN, and Cry11Aa proteins.
  • Molecular docking revealed overlapping binding sites for CTLGA9 and Cry11Aa on ALP1 and APN.
  • CTLGA9 significantly inhibited the larvicidal activity of Cry toxins.

Conclusions:

  • CTLGA9 acts as an antagonist to Cry toxins by competing for binding to ALP1 and APN receptors in A. aegypti.
  • This competitive inhibition reduces the mosquitocidal efficacy of Cry toxins.
  • Understanding CTLGA9's function provides insights into Cry toxin mechanisms and potential improvements for mosquito control strategies.
Keywords:
CTLGA9Cry11Aatoxicity

More Related Videos

Indel Detection following CRISPR/Cas9 Mutagenesis using High-resolution Melt Analysis in the Mosquito Aedes aegypti05:30

Indel Detection following CRISPR/Cas9 Mutagenesis using High-resolution Melt Analysis in the Mosquito Aedes aegypti

Published on: September 10, 2021

3.7K
Fat Body Organ Culture System in Aedes Aegypti, a Vector of Zika Virus06:18

Fat Body Organ Culture System in Aedes Aegypti, a Vector of Zika Virus

Published on: August 19, 2017

10.0K

Related Concept Videos

Drug-Receptor Interactions01:29

Drug-Receptor Interactions

Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
7.3K
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
4.9K
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.0K
Quantitative Aspects of Drug-Receptor Interaction01:30

Quantitative Aspects of Drug-Receptor Interaction

The receptor occupancy theory connects a drug's response to the number of occupied receptors. With higher drug concentrations, more receptors are occupied, leading to increased responses. The formation of drug-receptor complexes involves association and dissociation rates, which reach equilibrium when the forward and backward reactions are equal. The equilibrium association constant (Ka) and its inverse, the equilibrium dissociation constant (Kd), indicate drug affinity. Higher Ka and lower...
1.7K
Internal Receptors01:31

Internal Receptors

Many cellular signals are hydrophilic and therefore cannot pass through the plasma membrane. However, small or hydrophobic signaling molecules can cross the hydrophobic core of the plasma membrane and bind to internal, or intracellular, receptors that reside within the cell. Many mammalian steroid hormones use this mechanism of cell signaling, as does nitric oxide (NO) gas.
74.3K
Receptor-mediated Endocytosis01:39

Receptor-mediated Endocytosis

Overview
110.6K